October 07, 2025
1 min watch
In this video, Tycel Phillips, MD, discusses initial results of a phase 1b clinical trial focused on treating diffuse large B-cell lymphoma with a bispecific antibody and antibody-drug conjugate combination.
The findings were presented at the Society of Hematologic Oncology’s Annual Meeting.
“This is something, ideally, that maybe we can explore in early lines of therapy with patients,” Phillips, associate professor in the department of hematology and hematopoietic cell transplantation at City of Hope, said.
The LOTIS-7 trial is evaluating the combination of loncastuximab tesirine-lpyl (Zynlonta, ADC Therapeutics) plus glofitamab-gxbm (Columvi, Genentech) among patients with relapsed or refractory diffuse large B-cell lymphoma who had received at least one systematic therapy.
The researchers found that the combination had a “manageable” safety profile and a complete response rate of 90.9% among 22 efficacy-evaluable patients.
“If we look at historically what has been reported with glofitamab alone, this was a vast improvement in the safety of this medication, and sort of fits with the theme we’ve seen before, where antibody-drug conjugates seem to enhance the efficacy and the safety of bispecific antibodies,” Phillips said.
